Fonville Wealth Management LLC Sells 430 Shares of AbbVie Inc. $ABBV

Fonville Wealth Management LLC lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 24.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,365 shares of the company’s stock after selling 430 shares during the quarter. Fonville Wealth Management LLC’s holdings in AbbVie were worth $253,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. TD Capital Management LLC grew its position in shares of AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares in the last quarter. Marshall & Sullivan Inc. WA bought a new stake in shares of AbbVie in the second quarter valued at approximately $25,000. Spurstone Advisory Services LLC acquired a new stake in AbbVie during the second quarter worth approximately $28,000. Cypress Capital Management LLC WY acquired a new stake in AbbVie during the first quarter worth approximately $35,000. Finally, Bear Mountain Capital Inc. increased its stake in AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after acquiring an additional 173 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. The trade was a 19.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.25% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

ABBV has been the topic of several analyst reports. Berenberg Bank raised AbbVie from a “hold” rating to a “buy” rating and increased their target price for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research note on Monday, November 3rd. Hsbc Global Res cut shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Cantor Fitzgerald set a $250.00 price target on shares of AbbVie and gave the stock an “overweight” rating in a report on Thursday, October 9th. Finally, Morgan Stanley lifted their price objective on shares of AbbVie from $250.00 to $255.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $236.57.

AbbVie Trading Down 0.1%

ABBV opened at $218.92 on Friday. The company has a market cap of $386.92 billion, a P/E ratio of 104.25, a PEG ratio of 1.42 and a beta of 0.50. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. The company’s 50 day moving average is $223.24 and its 200-day moving average is $202.50. AbbVie Inc. has a 1-year low of $163.81 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the prior year, the firm earned $3.00 EPS. The firm’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is 524.24%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.